Enterofuryl, capsules 100 mg 30 pcs

Enterofuryl® is a broad-spectrum antimicrobial drug that has no systemic action and is used for treatment of diarrhea of infectious etiology. Enterofuryl® contains the active substance nifuroxazide, a drug of 5-nitrofuran derivatives group.

The drug has a bactericidal and bacteriostatic effect against most pathogens of acute intestinal infections. Antimicrobial action of nifuroxazide is dose-dependent: thus, low and medium doses of the drug have a bacteriostatic effect against pathogenic microflora, and high – bactericidal.
The bacteriostatic mechanism of action of the drug is associated with inhibition of dehydrogenase enzyme activity, which leads to disruption of the normal course of synthesis of vital compounds in the cell of the microorganism. Thus, due to the effect of nifuroxazide on a microorganism cell a disruption of the respiratory chain and inhibition of tricarboxylic acid cycle is observed.

Besides, Enterofuryl® inhibits protein synthesis in a microorganism cell and inhibits other biochemical processes in a bacterial cell. Thus, the microorganism cell loses its ability to reproduce.

Indications

Acute bacterial diarrhea, occurring without deterioration in general condition, increase in body temperature, or intoxication.

Pharmacological effect

Pharmacological action
Broad-spectrum antimicrobial drug, a derivative of 5-nitrofuran. Blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell. Destroys the microbial cell membrane, reduces the production of toxins by microorganisms. Highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp., Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolyticus, Staphylococcus spp. Weakly sensitive to nifuroxazide: Klebsiella spp., Proteus mirabilis, Providencia indologenes. Resistant to nifuroxazide: Klebsiella spp., Proteus mirabilis, Providencia spp., Pdeudomonas spp.
Does not disturb the balance of intestinal microflora.
In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Special instructions

When treating diarrhea, rehydration therapy must be carried out simultaneously with therapy with Enterofuril®. In case of bacterial diarrhea with signs of systemic damage, you should consult a doctor to decide on the use of systemic antibacterial drugs. If symptoms of hypersensitivity appear (shortness of breath, rash, itching), you should stop taking the drug. Drinking alcohol during therapy with nifuroxazide is prohibited.
Due to the content of methyl parahydroxybenzoate, the drug may cause allergic reactions (possibly delayed).
One capsule of Enterofuril® 100 mg contains 36 mg of sucrose, which corresponds to 0.0030 XE. In a single dose of the drug (2 capsules), the sucrose content corresponds to 0.0060 XE. The daily dose of sucrose is 0.024 XE for adults and children from 6 to 18 years of age when taking 2 capsules of Enterofuril® 100 mg 4 times a day, and 0.018 XE for children when taking 2 capsules of Enterofuril® 100 mg 3 times a day.

Impact on the ability to drive vehicles and machinery
The drug does not affect psychomotor activity and the ability to drive vehicles and operate machinery.

Active ingredient

Nifuroxazide

Composition

Active ingredient: nifuroxazide – 100 mg.
Excipients: sucrose – 36 mg, corn starch – 41.12 mg, powdered cellulose – 5.1 mg, magnesium stearate – 3.78 mg.
Composition of the capsule shell: titanium dioxide (E171) – 1.3333%, quinoline yellow dye (E104) – 0.7664%, azorubine dye (E122) – 0.0022%, crimson dye [Ponceau 4R] – 0.0077 mg, gelatin – q.s. up to 100%.

Pregnancy

The use of the drug Enterofuril during pregnancy is possible only in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus.

Enterofuril is not absorbed from the gastrointestinal tract and does not enter the systemic circulation, however, the use of the drug during lactation is possible only under strict indications, and the issue of stopping breastfeeding should be resolved.

Contraindications

Hypersensitivity to the components of the drug or other nitrofuran derivatives; fructose intolerance;
Glucose-galactose malabsorption syndrome or sucrase and isomaltase deficiency; pregnancy;
Age up to 1 month, premature newborns (oral suspension);
Children under 3 years of age (capsules).

Side Effects

Allergic reactions: rash, urticaria, Quincke’s edema, anaphylactic shock.

Interaction

Concomitant use with drugs that cause the development of disulfiram-like reactions or drugs that inhibit the function of the nervous system is not recommended. If you are taking other medications (including over-the-counter medications), consult your doctor before using this drug.

Overdose

Overdose symptoms are unknown. Treatment is symptomatic.

Short product description

Enterofuril® is a drug for initial treatment of intestinal infections. Eliminates the cause of diarrhea – harmful microbes and bacteria. Acts only in the intestinal lumen. Preserves normal intestinal microflora. Prevents the development of bacterial complications in viral diarrhea. More details at enterofuryl.ru

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

5 years

Manufacturer

Bosnalek JSC, Bosnia and Herzegovina